Cargando…

Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX

Three-dimensional spheroids of non-malignant MCF10A and malignant SKBR3 breast cells were used for subsequent 3D Cell-SELEX to generate aptamers for specific binding and treatment of breast cancer cells. Using 3D Cell-SELEX combined with Next-Generation Sequencing and bioinformatics, ten abundant ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelissen, Frank H. T., Peeters, Wenny J. M., Roelofs, Timo P., Nagelkerke, Anika, Span, Paul N., Heus, Hans A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068899/
https://www.ncbi.nlm.nih.gov/pubmed/33918832
http://dx.doi.org/10.3390/ph14040349
_version_ 1783683110736494592
author Nelissen, Frank H. T.
Peeters, Wenny J. M.
Roelofs, Timo P.
Nagelkerke, Anika
Span, Paul N.
Heus, Hans A.
author_facet Nelissen, Frank H. T.
Peeters, Wenny J. M.
Roelofs, Timo P.
Nagelkerke, Anika
Span, Paul N.
Heus, Hans A.
author_sort Nelissen, Frank H. T.
collection PubMed
description Three-dimensional spheroids of non-malignant MCF10A and malignant SKBR3 breast cells were used for subsequent 3D Cell-SELEX to generate aptamers for specific binding and treatment of breast cancer cells. Using 3D Cell-SELEX combined with Next-Generation Sequencing and bioinformatics, ten abundant aptamer families with specific structures were identified that selectively bind to SKBR3, and not to MCF10A cells. Multivalent aptamer polymers were synthesized by co-polymerization and analyzed for binding performance as well as therapeutic efficacy. Binding performance was determined by confocal fluorescence imaging and revealed specific binding and efficient internalization of aptamer polymers into SKBR3 spheroids. For therapeutic purposes, DNA sequences that intercalate the cytotoxic drug doxorubicin were co-polymerized into the aptamer polymers. Viability tests show that the drug-loaded polymers are specific and effective in killing SKBR3 breast cancer cells. Thus, the 3D-selected aptamers enhanced the specificity of doxorubicin against malignant over non-malignant breast cells. The innovative modular DNA aptamer platform based on 3D Cell SELEX and polymer multivalency holds great promise for diagnostics and treatment of breast cancer.
format Online
Article
Text
id pubmed-8068899
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80688992021-04-26 Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX Nelissen, Frank H. T. Peeters, Wenny J. M. Roelofs, Timo P. Nagelkerke, Anika Span, Paul N. Heus, Hans A. Pharmaceuticals (Basel) Article Three-dimensional spheroids of non-malignant MCF10A and malignant SKBR3 breast cells were used for subsequent 3D Cell-SELEX to generate aptamers for specific binding and treatment of breast cancer cells. Using 3D Cell-SELEX combined with Next-Generation Sequencing and bioinformatics, ten abundant aptamer families with specific structures were identified that selectively bind to SKBR3, and not to MCF10A cells. Multivalent aptamer polymers were synthesized by co-polymerization and analyzed for binding performance as well as therapeutic efficacy. Binding performance was determined by confocal fluorescence imaging and revealed specific binding and efficient internalization of aptamer polymers into SKBR3 spheroids. For therapeutic purposes, DNA sequences that intercalate the cytotoxic drug doxorubicin were co-polymerized into the aptamer polymers. Viability tests show that the drug-loaded polymers are specific and effective in killing SKBR3 breast cancer cells. Thus, the 3D-selected aptamers enhanced the specificity of doxorubicin against malignant over non-malignant breast cells. The innovative modular DNA aptamer platform based on 3D Cell SELEX and polymer multivalency holds great promise for diagnostics and treatment of breast cancer. MDPI 2021-04-09 /pmc/articles/PMC8068899/ /pubmed/33918832 http://dx.doi.org/10.3390/ph14040349 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nelissen, Frank H. T.
Peeters, Wenny J. M.
Roelofs, Timo P.
Nagelkerke, Anika
Span, Paul N.
Heus, Hans A.
Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX
title Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX
title_full Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX
title_fullStr Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX
title_full_unstemmed Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX
title_short Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX
title_sort improving breast cancer treatment specificity using aptamers obtained by 3d cell-selex
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068899/
https://www.ncbi.nlm.nih.gov/pubmed/33918832
http://dx.doi.org/10.3390/ph14040349
work_keys_str_mv AT nelissenfrankht improvingbreastcancertreatmentspecificityusingaptamersobtainedby3dcellselex
AT peeterswennyjm improvingbreastcancertreatmentspecificityusingaptamersobtainedby3dcellselex
AT roelofstimop improvingbreastcancertreatmentspecificityusingaptamersobtainedby3dcellselex
AT nagelkerkeanika improvingbreastcancertreatmentspecificityusingaptamersobtainedby3dcellselex
AT spanpauln improvingbreastcancertreatmentspecificityusingaptamersobtainedby3dcellselex
AT heushansa improvingbreastcancertreatmentspecificityusingaptamersobtainedby3dcellselex